1/24
Vocabulary-style practice flashcards covering key definitions, clinical features, diagnostic markers, radiologic signs, and pharmacologic mechanisms for Rheumatoid Arthritis and Systemic Lupus Erythematosus based on lecture materials.
Connective Tissue Disorders (CTD)
A group of autoimmune, multisystem, chronic, inflammatory diseases driven by an antibody or T-cell response directed against self-antigens, leading to tissue damage and organ failure.
Rheumatoid Arthritis (RA)
A chronic systemic inflammatory disease of unknown etiology characterized primarily by bilateral symmetric polyarthritis (synovitis) affecting the hands and feet.

Pannus
An exuberant proliferation and inflammation of the synovial membrane that leads to the destruction of articular tissues, including cartilage, bone, tendons, ligaments, and blood vessels.
Shared Epitope (RA Genetics)
A specific sequence motif in human leukocyte antigen (HLA)-DR4 and HLA-DR1 alleles that accounts for approximately 50% of the genetic risk for developing rheumatoid arthritis.
Felty Syndrome
A severe clinical triad variant of rheumatoid arthritis consisting of rheumatoid arthritis, splenomegaly, and neutropenia (leukopenia).
Rheumatoid Factor (RF)
An autoantibody, usually an IgM immunoglobulin, directed against the Fc fragment of IgG; it is present in roughly 60–80% of patients with rheumatoid arthritis.
Anti-Citrullinated Protein Antibodies (ACPA / Anti-CCP)
Highly specific diagnostic autoantibodies for rheumatoid arthritis that predict the radiographic progression of bone erosions independent of disease activity.
Lanoise Deformity
Fibular drift of the toes, a musculoskeletal deformity observed in the feet of patients with rheumatoid arthritis.

Radiographic Hallmarks of RA
Characteristic plain X-ray findings in rheumatoid arthritis including soft tissue swelling, periarticular osteopenia, joint space narrowing, and marginal erosions.
Methotrexate (MTX)
A conventional synthetic DMARD that inhibits dihydrofolate reductase to decrease folate-dependent DNA/RNA synthesis and increase anti-inflammatory adenosine levels.
Leflunomide
A DMARD that inhibits dihydroorotate dehydrogenase, blocking pyrimidine synthesis and thereby inhibiting T and B cell proliferation.
Sulfasalazine
A DMARD converted to 5-ASA in the colon that exerts anti-inflammatory action by inhibiting NF-κB and cytokine production.
Hydroxychloroquine (HCQ)
An antimalarial DMARD that increases lysosomal pH to inhibit antigen presentation; recommended for all SLE patients at doses ≤5mg/kg/day.
Mycophenolate Mofetil (MMF)
An immunosuppressive cell-cycle inhibitor that blocks inosine monophosphate dehydrogenase, selectively inhibiting de novo purine synthesis in lymphocytes.
Cyclophosphamide
An alkylating agent that cross-links DNA to inhibit rapidly dividing B and T lymphocytes, used for organ-threatening manifestations in connective tissue diseases.
Tocilizumab
A biologic DMARD that inhibits IL-6-mediated signaling and inflammation by blocking both soluble and membrane-bound IL-6 receptors.
Tofacitinib
A targeted synthetic DMARD (tsDMARD) that inhibits Janus kinases (JAK1/JAK3) to block the intracellular signaling pathways of multiple cytokines.
Systemic Lupus Erythematosus (SLE)
A chronic multisystem autoimmune disease characterized by autoantibodies against nuclear and cytoplasmic antigens, predominantly affecting women of childbearing age (female-to-male ratio of 11:1).

Malar Rash
An erythematous cutaneous lesion characteristically appearing over the cheeks and nasal bridge while sparing the nasolabial folds, seen in acute cutaneous lupus.
Subacute Cutaneous Lupus
A dermatologic manifestation of SLE presenting as annular or psoriasiform patches with crusted margins, typically occurring on sun-exposed areas of the limbs or torso.
Libman-Sacks Endocarditis
A noninfectious form of endocarditis characterized by sterile valvular vegetations in patients with systemic lupus erythematosus.
Antinuclear Antibodies (ANA)
The essential screening entry criterion for EULAR/ACR SLE classification (titer ≥1:80 on HEp-2 cells), possessing approximately 95% sensitivity for SLE.
Anti-dsDNA Antibodies
Highly specific autoantibodies for SLE (sensitivity ~70%) whose serum levels fluctuate parallel to underlying clinical disease activity.
Anti-Sm Antibodies
The most specific autoantibody marker for systemic lupus erythematosus, present in approximately 30–40% of SLE patients.
Synovial Fluid Analysis in RA
Laboratory evaluation of joint fluid revealing inflammatory counts (WBC 2,000–50,000/μL) with 60–80% neutrophil predominance and characteristically low glucose levels relative to serum.